In addition, GBM is characterized by extensive genetic heterogeneity, and some targeted therapies for traditional molecules, such as inhibition of EGFR and PI3K, do not benefit clinical GBM patients (Stupp et al., 2005; McNamara et al., 2014; Li et al., 2016; Westphal et al., 2017). The gene discussed is EGFR; the disease is glioblastoma.